PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
6 hedge funds and large institutions have $29.2K invested in PDL BioPharma, Inc. in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
5% more capital invested
Capital invested by funds: $28K → $29.2K (+$1.26K)
25% less funds holding
Funds holding: 8 → 6 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DT
Diversified Trust
Memphis,
Tennessee
|
+$1.26K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DT
1
Diversified Trust
Memphis,
Tennessee
| $27.7K | +$1.26K | +525 | +5% |
|
2
RhumbLine Advisers
Boston,
Massachusetts
| $1.51K | – | – | – |
|
PDLI Hedge Fund Activity: Q1 2026 in Review
6 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q1 2026, worth a combined $29.2K — up 4.5% from $28K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PDLI and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Diversified Trust, adding an estimated $1.26K.
- 6 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q1 2026, down from 8 in Q4 2025.
- Funds reported $29.2K of PDL BioPharma, Inc. stock for Q1 2026, up 4.5% quarter-over-quarter.
- 0 funds opened new PDL BioPharma, Inc. positions in Q1 2026 and 1 closed out, a net change of -1 holder.
- The largest PDL BioPharma, Inc. buyer in Q1 2026 was Diversified Trust, an estimated $1.26K added.
Based on aggregated 13F filings for Q1 2026.